fate therapeutics stock price target

In terms of how Fate Therapeutics Inc fares relative to Pharmaceutical Products stocks note that its average analyst price target is greater than 94038 of that group. Fate Therapeutics has only been the subject of 3 research reports in the past 90 days.

Why Fate Therapeutics Stock Is Sliding Today The Motley Fool

AFTER HOURS 707 PM EDT 031622.

. Morgan Stanley lowered their price target on shares of Fate Therapeutics from 7400 to 6200 and set an equal weight rating for the company in a research report on Wednesday December 15th. HC Wainwright Adjusts Fate Therapeutics Price Target to 115 from 122 Keeps Buy Rati. HC Wainwright Adjusts Fate Therapeutics Price Target to 115 from 122 Keeps Buy Rating 847AM ET 3042022 MT Newswires Fate Therapeutics FATE has an average rating of buy and price targets ranging from 42 to 135 according to analysts polled by Capital IQ.

Nasdaq AT CLOSE 400 PM EDT 031622. Morgan Stanley Adjusts Fate Therapeutics Price Target to 52 From 62 Maintains Equalw. Fate Therapeutics stock price target raised to 88 from 55 at Wedbush Dec.

The average price target is 000 with a high estimate of 000 and a low estimate of 000. Wedbush increased their price target on Fate Therapeutics from 7400 to 7700 and gave the stock an outperform rating in a research note on Tuesday March 1st. Below is a summary of how these 4 analysts rated Fate Therapeutics over the.

The stock has traded between 3832 and 3995 so far today. ET by Tomi Kilgore Fate Therapeutics stock price target raised to 65 from 40 at Truist. FATE stock price quote with breaking news financials statistics charts and more.

1y Target Est 9453 Fair Value is the appropriate price for the shares of a company based on its earnings and growth rate also interpreted as when PE Ratio Growth Rate. 7 2020 at 718 am. Sign in to your SmartPortfolio to see more analyst recommendations.

HC Wainwright reduced their target price on shares of Fate Therapeutics from 12200 to 11500 and set a buy rating on the stock in a research report on Friday March 4th. The average price target for FATE is 95071 and analysts rate the stock as a Strong Buy. Stocks similar to Fate Therapeutics Inc in the Pharmaceutical.

5 Wall Street analysts that have issued a 1 year FATE price target the average FATE price target is 9360 with the highest FATE stock price forecast at 11500 and the lowest FATE stock price forecast at 7400. Volume today is below average. Get a real-time Fate Therapeutics Inc.

FATE has a higher upside potential average analyst target price relative to current price than 100215 of stocks in the mid market cap category. Fate Therapeutics Inc FATE stock is trading at 3859 as of 940 AM on Friday Feb 11 an increase of 047 or 125 from the previous closing price of 3811. Analyst Recommendations on FATE THERAPEUTICS INC.

The company has an average price target of 9325 with a high of 12200 and a low of 6200. Wedbush Adjusts Fate Therapeutics Price Target to 77 From 74 Keeps Outperform Ratin. Ad 1000 Strong Buy Stocks that Double the SP.

Get a real-time Fate Therapeutics Inc. InvestorsObserver is giving Fate Therapeutics Inc FATE an Analyst Rating Rank of 59 meaning FATE is ranked higher by analysts than 59 of stocks. FATE stock price quote with breaking news financials statistics charts and more.

9679 1342 Earnings Date. Get the latest Fate Therapeutics stock price and detailed information including FATE news historical charts and realtime prices. According to analysts consensus price target of 9500 Fate Therapeutics has a forecasted upside of 1401 from its current price of 3957.

The average twelve-month price target for Fate Therapeutics is 9500 with a high price target of 14500 and a low price target of 6000. 69 rows Given the current short-term trend the stock is expected to fall. Amount of Analyst Coverage.

According to the issued ratings of 9 analysts in the last year the consensus rating for Fate Therapeutics stock is Buy based on the current 2 hold ratings and 7 buy ratings for FATE.

The Rally Likely To Continue For Fate Therapeutics After Positive Clinical Trials Data Nasdaq